A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma
Public ClinicalTrials.gov record NCT02954406. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of TAK-659 when administered in combination with bendamustine, bendamustine + rituximab, gemcitabine, lenalidomide, or ibrutinib.
Study identification
- NCT ID
- NCT02954406
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 43 participants
Conditions and interventions
Conditions
Interventions
- TAK-659 Drug
- Bendamustine Drug
- Rituximab Drug
- Gemcitabine Drug
- Lenalidomide Drug
- Ibrutinib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 5, 2017 (Actual)
- Primary completion
- Jul 27, 2020 (Actual)
- Completion
- Jul 27, 2020 (Actual)
- Last update posted
- Feb 18, 2022
2017 – 2020
United States locations
- U.S. sites
- 11
- U.S. states
- 10
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Arizona Cancer Center, Tucson | Tucson | Arizona | 85724 | — |
| University of California San Diego (UCSD) - Moores Cancer Center | La Jolla | California | 92093 | — |
| Cedars-Sinai Medical Center (CSMC) - Samuel Oschin Comprehensive Cancer Institute | West Hollywood | California | 90048 | — |
| University of Louisville Kentucky James Graham Brown Cancer Center | Louisville | Kentucky | 40202 | — |
| Center for Cancer and Blood Disorders | Bethesda | Maryland | 20817 | — |
| Tufts Medical Center | Boston | Massachusetts | 02111 | — |
| Henry Ford Hospital | Detroit | Michigan | 48202-2608 | — |
| NYU Langone Medical Center - NYU Medical Oncology Associates | New York | New York | 10016-4744 | — |
| University of North Carolina - Lineberger Comprehensive Cancer Center | Chapel Hill | North Carolina | 27514 | — |
| University Hospitals of Cleveland | Cleveland | Ohio | 44106 | — |
| West Virginia University | Morgantown | West Virginia | 26506 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02954406, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 18, 2022 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02954406 live on ClinicalTrials.gov.